Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
Upcoming SlideShare
Loading in...5
×
 

Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

on

  • 166 views

 

Statistics

Views

Total Views
166
Views on SlideShare
166
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture Document Transcript

  • Japan In Vitro Diagnostics Market Outlook to 2018- ClinicalChemistry Genetic Testing, Haematology, Histology andCytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureReport Details:Published:November 2012No. of Pages: 270Price: Single User License – US$2500Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing,Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureSummaryGlobalData’s new report, “Japan In Vitro Diagnostics Market Outlook to 2018- Clinical ChemistryGenetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, InfectiousImmunology and Microbiology Culture” provides key market data on the Japan In Vitro Diagnosticsmarket. The report provides value (USD million) data for each segment and sub-segment withinseven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology AndCytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report alsoprovides company shares and distribution shares data for each of the aforementioned marketcategories. The report is supplemented with global corporate-level profiles of the key marketparticipants with information on company financials and pipeline products, wherever available.This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GlobalData’s team of industry experts.Scope- Market size and company share data for In Vitro Diagnostics market categories – ClinicalChemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, InfectiousImmunology and Microbiology Culture.- Annualized market revenues (USD million) data for each of the segments and sub-segmentswithin seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • - 2011 company shares and distribution shares data for each of the seven market categories.- Global corporate-level profiles of key companies operating within the Japan In VitroDiagnosticsmarket.- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, AbbottLaboratories, Sysmex Corporation, Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc. andothers.Reasons to buy- Develop business strategies by identifying the key market categories and segments poised forstrong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the Japan In Vitro Diagnosticscompetitive landscape.- Develop capital investment strategies by identifying the key market segments expected toregister strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of productdistribution – Identify, understand and capitalize.Get your copy of this report @http://www.reportsnreports.com/reports/210642-japan-in-vitro-diagnostics-market-outlook-to-2018-clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-microbiology-culture.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 21.1 List of Tables 91.2 List of Figures 142 Introduction 172.1 What is This Report About? 173 In Vitro Diagnostics In Japan 183.1 In Vitro Diagnostics, Market Segmentation 183.2 In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 193.3 In Vitro Diagnostics Market, Japan, Revenue Mix ($m), 2011 213.4 In Vitro Diagnostics Market, Japan, Category Contribution (%), 2011 223.5 In Vitro Diagnostics, Japan, Company Share (2010-2011) 294 Clinical Chemistry In Japan 314.1 Clinical Chemistry, Market Segmentation 314.2 Clinical Chemistry Market, Japan, Revenue Mix ($m), 2011 324.3 Clinical Chemistry Market, Japan, Segment Contribution (%), 2011 334.4 Clinical Chemistry Overall Revenue, (2004-2018) 344.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 384.4.2 Urine Analysis, Revenue (2004-2018) 42
  • 4.5 Clinical Chemistry Distribution Share (2010-2011) 444.6 Clinical Chemistry, Japan, Company Share (2010-2011) 455 Genetic Testing In Japan 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, Japan, Revenue Mix ($m), 2011 485.3 Genetic Testing Market, Japan, Segment Contribution (%), 2011 495.4 Genetic Testing Overall Revenue, (2004-2018) 505.5 Genetic Testing Distribution Share (2010-2011) 545.6 Genetic Testing, Japan, Company Share (2010-2011) 556 Haematology In Japan 566.1 Haematology Market, Market Segmentation 566.2 Haematology Market, Japan, Revenue Mix ($m), 2011 576.3 Haematology Market, Japan, Segment Contribution (%), 2011 586.4 Haematology Overall Revenue, (2004-2018) 596.4.1 Haematology Reagents, Revenue (2004-2018) 636.4.2 Immunohaematology, Revenue (2004-2018) 676.4.3 Haemostasis, Revenue (2004-2018) 716.4.4 Haematology Rapid Tests, Revenue (2004-2018) 756.4.5 Haematology Cell Counters, Revenue (2004-2018) 796.5 Haematology Distribution Share (2010-2011) 836.6 Haematology, Japan, Company Share (2010-2011) 847 Histology And Cytology In Japan 867.1 Histology and Cytology Market, Market Segmentation 867.2 Histology And Cytology Market, Japan, Revenue Mix ($m), 2011 877.3 Histology And Cytology Market, Japan, Segment Contribution (%), 2011 887.4 Histology And Cytology Overall Revenue, (2004-2018) 897.5 Histology And Cytology Distribution Share (2010-2011) 937.6 Histology And Cytology, Japan, Company Share (2010-2011) 948 Immuno Chemistry In Japan 968.1 Immuno Chemistry Market, Japan, Revenue Mix ($m), 2011 968.2 Immuno Chemistry Market, Japan, Segment Contribution (%), 2011 978.3 Immuno Chemistry Overall Revenue, (2004-2018) 998.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 1038.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 1078.3.3 Endocrinology Tests, Revenue (2004-2018) 1118.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 1158.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 1198.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 1238.4 Immuno Chemistry Distribution Share (2010-2011) 1278.5 Immuno Chemistry, Japan, Company Share (2010-2011) 1289 Infectious Immunology In Japan 1309.1 Infectious Immunology, Market Segmentation 130
  • 9.2 Infectious Immunology Market, Japan, Revenue Mix ($m), 2011 1319.3 Infectious Immunology Market, Japan, Segment Contribution (%), 2011 1329.4 Infectious Immunology Overall Revenue, (2004-2018) 1339.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 1379.5 Infectious Immunology Distribution Share (2010-2011) 1419.6 Infectious Immunology, Japan, Company Share (2010-2011) 14210 Microbiology Culture In Japan 14410.1 Microbiology Culture, Market Segmentation 14410.2 Microbiology Culture Market, Japan, Revenue Mix ($m), 2011 14510.3 Microbiology Culture Market, Japan, Segment Contribution (%), 2011 14610.4 Microbiology Culture Overall Revenue, (2004-2018) 14710.4.1 Microbiology Analyzers, Revenue (2004-2018) 15110.5 Microbiology Culture Distribution Share (2010-2011) 15510.6 Microbiology Culture, Japan, Company Share (2010-2011) 15611 Overview of Key Companies in Japan In Vitro Diagnostics Market 15811.1 F. Hoffmann-La Roche Ltd. 15811.1.1 Company Overview 15811.1.2 Share in the Japan In Vitro Diagnostics Market 15811.2 Siemens Healthcare 15911.2.1 Company Overview 15911.2.2 Share in the Japan In Vitro Diagnostics Market 15911.3 Abbott Laboratories 16011.3.1 Company Overview 16011.3.2 Share in the Japan In Vitro Diagnostics Market 16011.4 Sysmex Corporation 16111.4.1 Company Overview 16111.4.2 Share in the Japan In Vitro Diagnostics Market 16111.5 Ortho-Clinical Diagnostics Inc. 16211.5.1 Company Overview 16211.5.2 Share in the Japan In Vitro Diagnostics Market 16211.6 Beckman Coulter, Inc. 16311.6.1 Company Overview 16311.6.2 Share in the Japan In Vitro Diagnostics Market 16311.7 Eiken Chemical Co.,Ltd. 16411.7.1 Company Overview 16411.8 Becton, Dickinson and Company 16411.8.1 Company Overview 16411.9 Bio-Rad Laboratories, Inc. 16511.9.1 Company Overview 16511.10 bioMerieux S.A. 16511.10.1 Company Overview 16511.11 Nihon Kohden Corporation 166
  • 11.11.1 Company Overview 16611.12 Alere Inc. 16611.12.1 Company Overview 16611.13 DiaSorin S.p.A 16711.13.1 Company Overview 16711.14 Olympus Corporation 16711.14.1 Company Overview 16711.15 Horiba, Ltd. 16811.15.1 Company Overview 16811.16 Tosoh Corporation 16811.16.1 Company Overview 16811.17 Qiagen N.V. 16911.17.1 Company Overview 16911.18 Gen-Probe Incorporated 16911.18.1 Company Overview 16911.19 Mindray Medical International Limited 17011.19.1 Company Overview 17011.20 PerkinElmer, Inc. 17011.20.1 Company Overview 17011.21 Danaher Corporation 17111.21.1 Company Overview 17111.22 Grifols, S.A. 17111.22.1 Company Overview 17111.23 Diagnostica Stago, Inc. 17211.23.1 Company Overview 17211.24 Life Technologies Corporation 17211.24.1 Company Overview 17212 In Vitro Diagnostics Market Pipeline Products 17312.1 Clinical Chemisty Market Pipeline Products 17312.2 Immuno Chemistry Market Pipeline Products 17612.3 Haematology Market Pipeline Products 18512.4 Infectious Immunology Market Pipeline Products 18712.5 Microbiology Culture Market Pipeline Products 19412.6 Histology And Cytology Market Pipeline Products 19512.7 Genetic Testing Market Pipeline Products 19613 Financial Deals Landscape 20113.1 Partnerships 20113.1.1 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 20113.1.2 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 20313.1.3 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 20413.1.4 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
  • Assays 20513.1.5 Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling AndDiagnostic Discovery 20613.1.6 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpressDx Test 20713.1.7 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology20913.1.8 CML HealthCare Enters Into Agreement With MaRS Innovation 21013.1.9 Akrivis Technologies Enters Into Co-Development Agreement With United States Biological21113.1.10 Castle Biosciences Enters Into Licensing Agreement With Brigham and Womens HospitalFor Mesothelioma Test 21213.1.11 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 21313.1.12 GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 21413.1.13 Dolomite Centre Enters Into Licensing Agreement With Japan Science and TechnologyAgency For Microdroplet Generation Technology 21513.1.14 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TBTest 21613.1.15 Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 21713.1.16 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 21813.1.17 Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems21913.1.18 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 22013.1.19 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 22113.1.20 Guided Therapeutics Extends Licensing And Co-Development Agreement With KonicaMinolta 22213.1.21 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus22313.1.22 Immuno-Biological Labs To Form Joint Venture With TransGenic 22413.1.23 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 22513.1.24 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POCTest 22613.1.25 One Lambda Enters Into Co-Marketing Agreement With CellTrend 22713.1.26 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics ForALK Cancer Biomarker 22813.1.27 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 22913.1.28 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker23013.1.29 Pacific Biosciences Enters Into Co-Marketing Agreement With Tomy Digital Biology 231
  • 13.1.30 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor CellTechnology 23213.1.31 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 23313.1.32 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRangePCR Kit 23413.1.33 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 23513.1.34 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 23613.1.35 Ezose Sciences Enters Into Co-Development Agreement With Hirosaki University ForNew Cancer Biomarkers 23713.1.36 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 23813.1.37 GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 23913.1.38 Metabolon Enters Into Co-Development Agreement With Takeda Pharma 24013.1.39 GE Healthcare Enters Into Research Agreement With Clino 24113.1.40 NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 24213.1.41 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 24313.1.42 Molecular Response Enters Into Co-Marketing Agreement With Transparent 24413.1.43 Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure ChemicalIndustries 24514 Recent Developments 24614.1 Strategy And Business Planning 24614.1.1 Oct 10, 2012: Eisai Group To Transform Product Creation Structure To Reflect Focus OnPersonalized Medicine 24614.1.2 Jul 05, 2012: Shionogi Launches New European Headquarters In London 24614.1.3 Apr 17, 2012: 3-D Matrix Establishes Wholly Owned New Subsidiary In France 24714.1.4 Jan 19, 2012: Nihon Kohden Establishes Sales Subsidiary In Brazil 24714.1.5 Nov 28, 2011: Shionogi To Announce Corporate Reorganization 24714.2 Research And Development 24814.2.1 Apr 23, 2012: Ezose And Hirosaki University To Collaborate In Glycomics Research ToFind New Cancer Biomarkers 24814.3 Government and Public Interest 24914.3.1 Nov 08, 2012: New Portable Device Enables RNA Detection From Ultra-Small Sample InOnly 20 Minutes 24914.4 Product News 25014.4.1 Aug 27, 2012: ARKRAY To Launch i-densy IS – 5320 Gene Analyzer 25014.4.2 Jun 13, 2012: Fluidigm Introduces C1 Single-Cell AutoPrep System To Researchers AtISSCR 25014.4.3 Feb 08, 2012: Alverix’s Partner BD Receives Japanese Regulatory Approval For BD VeritorSystem For Flu A+B 25114.4.4 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion
  • Diagnostic To Guide Cancer Treatments 25214.4.5 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR CompanionDiagnostic To Guide Cancer Treatments 25214.4.6 Jul 22, 2011: Sysmex Launches Automated Blood Coagulation Analyzer CS-5100 25314.4.7 May 10, 2011: Life Technologies Launches 3500 Dx Series Genetic Analyzer In Japan 25314.4.8 May 10, 2011: Life Technologies Launches 7500 Fast Dx Real-Time PCR Instrument InJapan 25415 Appendix 25515.1 Definitions of Markets Covered in the Report 25615.1.1 In Vitro Diagnostics 25615.2 Research Methodology 26715.3 Secondary Research 26715.4 Primary Research 26815.5 Models 26815.6 Forecasts 26915.7 Expert Panels 26915.8 GlobalData Consulting 26915.9 Currency Conversion 27015.10 Contact Us 27015.11 Disclaimer 2701.1 List of TablesTable 1: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 20Table 2: In Vitro Diagnostics Market, Japan, Category Contribution (%), 2011 22Table 3: In Vitro Diagnostics Market, Japan, Cross-Category Analysis, 2004-2018 24Table 4: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Historic, 2004-201126Table 5: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Forecast, 2011-201828Table 6: In Vitro Diagnostics, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 30Table 7: Clinical Chemistry Market, Japan, Segment Contribution (%), 2011 33Table 8: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 35Table 9: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 37Table 10: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 39Table 11: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 41Table 12: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 42
  • Table 13: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 43Table 14: Clinical Chemistry, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 44Table 15: Clinical Chemistry, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 46Table 16: Genetic Testing Market, Japan, Segment Contribution (%), 2011 49Table 17: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-201151Table 18: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53Table 19: Genetic Testing, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-201154Table 20: Genetic Testing, Japan, Company Share by Revenue ($m), USD Constant, 2010-201155Table 21: Haematology Market, Japan, Segment Contribution (%), 2011 58Table 22: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-201160Table 23: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-201862Table 24: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 64Table 25: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 66Table 26: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 68Table 27: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 70Table 28: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 72Table 29: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 74Table 30: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 76Table 31: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 78Table 32: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 80Table 33: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 82Table 34: Haematology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-201183
  • Table 35: Haematology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 85Table 36: Histology And Cytology Market, Japan, Segment Contribution (%), 2011 88Table 37: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 90Table 38: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 92Table 39: Histology And Cytology, Japan, Distribution Share by Revenue ($m), USD Constant,2010-2011 93Table 40: Histology And Cytology, Japan, Company Share by Revenue ($m), USD Constant,2010-2011 95Table 41: Immuno Chemistry Market, Japan, Segment Contribution (%), 2011 98Table 42: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 100Table 43: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 102Table 44: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 104Table 45: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 106Table 46: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 108Table 47: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 110Table 48: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 112Table 49: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 114Table 50: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 116Table 51: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 118Table 52: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 120Table 53: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 122Table 54: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 124Table 55: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 126Table 56: Immuno Chemistry, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 127Table 57: Immuno Chemistry, Japan, Company Share by Revenue ($m), USD Constant, 2010-
  • 2011 129Table 58: Infectious Immunology Market, Japan, Segment Contribution (%), 2011 132Table 59: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 134Table 60: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 136Table 61: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138Table 62: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 140Table 63: Infectious Immunology, Japan, Distribution Share by Revenue ($m), USD Constant,2010-2011 141Table 64: Infectious Immunology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 143Table 65: Microbiology Culture Market, Japan, Segment Contribution (%), 2011 146Table 66: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 148Table 67: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 150Table 68: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 152Table 69: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 154Table 70: Microbiology Culture, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 155Table 71: Microbiology Culture, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 157Table 72: Clinical Chemisty Market Pipeline Products 173Table 73: Immuno Chemistry Market Pipeline Products 176Table 74: Haematology Market Pipeline Products 185Table 75: Infectious Immunology Market Pipeline Products 187Table 76: Microbiology Culture Market Pipeline Products 194Table 77: Histology And Cytology Market Pipeline Products 195Table 78: Genetic Testing Market Pipeline Products 196Table 79: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 201Table 80: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 203Table 81: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 204Table 82: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New OncologyAssays 205Table 83: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling AndDiagnostic Discovery 206
  • Table 84: Med BioGene Amends Licensing Agreement With Precision Therapeutics ForLungExpress Dx Test 207Table 85: Ovizio Imaging Systems Enters Into Distribution Agreement With ApplikonBiotechnology 209Table 86: CML HealthCare Enters Into Agreement With MaRS Innovation 210Table 87: Akrivis Technologies Enters Into Co-Development Agreement With United StatesBiological 211Table 88: Castle Biosciences Enters Into Licensing Agreement With Brigham and WomensHospital For Mesothelioma Test 212Table 89: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 213Table 90: GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 214Table 91: Dolomite Centre Enters Into Licensing Agreement With Japan Science and TechnologyAgency For Microdroplet Generation Technology 215Table 92: Epistem Enters Into Distribution Agreement With Becton Dickinson For MycobacteriumTB Test 216Table 93: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 217Table 94: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 218Table 95: Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys DiagnosticSystems 219Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 220Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test221Table 98: Guided Therapeutics Extends Licensing And Co-Development Agreement With KonicaMinolta 222Table 99: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus223Table 100: Immuno-Biological Labs To Form Joint Venture With TransGenic 224Table 101: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 225Table 102: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4POC Test 226Table 103: One Lambda Enters Into Co-Marketing Agreement With CellTrend 227Table 104: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight GeneticsFor ALK Cancer Biomarker 228Table 105: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 229Table 106: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERGMarker 230Table 107: Pacific Biosciences Enters Into Co-Marketing Agreement With Tomy Digital Biology231Table 108: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
  • Cell Technology 232Table 109: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 233Table 110: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen ForLongRange PCR Kit 234Table 111: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 235Table 112: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 236Table 113: Ezose Sciences Enters Into Co-Development Agreement With Hirosaki University ForNew Cancer Biomarkers 237Table 114: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 238Table 115: GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 239Table 116: Metabolon Enters Into Co-Development Agreement With Takeda Pharma 240Table 117: GE Healthcare Enters Into Research Agreement With Clino 241Table 118: NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 242Table 119: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 243Table 120: Molecular Response Enters Into Co-Marketing Agreement With Transparent 244Table 121: Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure ChemicalIndustries 2451.2 List of FiguresFigure 1: In Vitro Diagnostics, Market Segmentation 18Figure 2: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 19Figure 3: In Vitro Diagnostics Market, Japan, Revenue Mix ($m), 2011 21Figure 4: In Vitro Diagnostics Market, Japan, Category Contribution (%), 2011 22Figure 5: In Vitro Diagnostics Market, Japan, Cross-Category Analysis, 2004-2018 23Figure 6: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Historic, 2004-201125Figure 7: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Forecast, 2011-201827Figure 8: In Vitro Diagnostics, Japan, Company Share (%), 2011 29Figure 9: Clinical Chemistry, Market Segmentation 31Figure 10: Clinical Chemistry Market, Japan, Revenue Mix ($m), 2011 32Figure 11: Clinical Chemistry Market, Japan, Segment Contribution (%), 2011 33Figure 12: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 34Figure 13: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 36Figure 14: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 38Figure 15: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,
  • Forecast, 2011-2018 40Figure 16: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 42Figure 17: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 43Figure 18: Clinical Chemistry, Japan, Company Share (%), 2011 45Figure 19: Genetic Testing, Market Segmentation 47Figure 20: Genetic Testing Market, Japan, Revenue Mix ($m), 2011 48Figure 21: Genetic Testing Market, Japan, Segment Contribution (%), 2011 49Figure 22: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 50Figure 23: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 52Figure 24: Genetic Testing, Japan, Company Share (%), 2011 55Figure 25: Haematology Market, Market Segmentation 56Figure 26: Haematology Market, Japan, Revenue Mix ($m), 2011 57Figure 27: Haematology Market, Japan, Segment Contribution (%), 2011 58Figure 28: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-201159Figure 29: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-201861Figure 30: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 63Figure 31: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 65Figure 32: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 67Figure 33: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 69Figure 34: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 71Figure 35: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 73Figure 36: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 75Figure 37: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 77Figure 38: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 79Figure 39: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 81Figure 40: Haematology, Japan, Company Share (%), 2011 84
  • Figure 41: Histology and Cytology Market, Market Segmentation 86Figure 42: Histology And Cytology Market, Japan, Revenue Mix ($m), 2011 87Figure 43: Histology And Cytology Market, Japan, Segment Contribution (%), 2011 88Figure 44: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 89Figure 45: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 91Figure 46: Histology And Cytology, Japan, Company Share (%), 2011 94Figure 47: Immuno Chemistry Market, Japan, Revenue Mix ($m), 2011 96Figure 48: Immuno Chemistry Market, Japan, Segment Contribution (%), 2011 97Figure 49: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 99Figure 50: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 101Figure 51: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 103Figure 52: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 105Figure 53: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 107Figure 54: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 109Figure 55: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic,2004-2011 111Figure 56: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast,2011-2018 113Figure 57: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 115Figure 58: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 117Figure 59: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 119Figure 60: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 121Figure 61: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 123Figure 62: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 125Figure 63: Immuno Chemistry, Japan, Company Share (%), 2011 128Figure 64: Infectious Immunology, Market Segmentation 130Figure 65: Infectious Immunology Market, Japan, Revenue Mix ($m), 2011 131Figure 66: Infectious Immunology Market, Japan, Segment Contribution (%), 2011 132
  • Figure 67: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 133Figure 68: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 135Figure 69: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 137Figure 70: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 139Figure 71: Infectious Immunology, Japan, Company Share (%), 2011 142Figure 72: Microbiology Culture, Market Segmentation 144Figure 73: Microbiology Culture Market, Japan, Revenue Mix ($m), 2011 145Figure 74: Microbiology Culture Market, Japan, Segment Contribution (%), 2011 146Figure 75: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 147Figure 76: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 149Figure 77: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 151Figure 78: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 153Figure 79: Microbiology Culture, Japan, Company Share (%), 2011 156Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Japan In Vitro DiaContact: sales@reportsandreports.com for more information.